Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) traded down 9.1% during trading on Thursday . The company traded as low as $0.54 and last traded at $0.60. 774,899 shares traded hands during trading, an increase of 83% from the average session volume of 423,503 shares. The stock had previously closed at $0.66.
A number of equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective (down from $5.00) on shares of Eyegate Pharmaceuticals in a research note on Tuesday, February 6th. ValuEngine raised Eyegate Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
The company has a debt-to-equity ratio of 0.01, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market capitalization of $10.32, a P/E ratio of -0.54 and a beta of 2.91.
An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. boosted its holdings in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 0.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 247,319 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,988 shares during the period. Vanguard Group Inc. owned approximately 2.27% of Eyegate Pharmaceuticals worth $339,000 as of its most recent filing with the Securities and Exchange Commission. 11.94% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.com-unik.info/2018/02/17/eyegate-pharmaceuticals-eyeg-shares-down-9-1.html.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.